Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.
Core Innovation
The invention relates to a humanized BCMA (PMC306) scFv comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 5. It further relates to an anti-BCMA CAR fusion protein that includes the PMC306 scFv and an engineered domain architecture.
The CAR fusion protein includes a transmembrane domain and one or more co-stimulatory domains, and a CD3ζ activating domain. The described architecture is used to generate humanized BCMA-CAR-T cells expressing the anti-BCMA CAR fusion protein with defined cytotoxicity and IFN-γ secretion against BCMA-positive tumor cells.
In supporting in vivo findings described in the partial content, humanized BCMA-CAR-T cells show decreased RPMI8226 xenograft tumor growth in NSG mice, with no apparent mouse weight loss reported. The partial content also indicates supporting CAR sequence/domain architecture and binding/functional readouts including FACS detection of BCMA binding.
Claims Coverage
The independent claim covers a method of decreasing the growth of a BCMA-positive tumor by contacting the tumor with engineered immune cells expressing an anti-BCMA CAR with a specified humanized anti-BCMA scFv (VH=SEQ ID NO:3 and VL=SEQ ID NO:5) and a defined CAR domain architecture consisting of a selectable transmembrane domain, a selectable co-stimulatory domain, and a CD3ζ activating domain. The dependent claims refine the immune-cell type and further constrain CAR component selections.
Decreasing growth of a BCMA-positive tumor with an anti-BCMA CAR scFv defined by SEQ ID NO: 3 and SEQ ID NO: 5
A method of decreasing growth of a BCMA-positive tumor by contacting the tumor with engineered immune cells expressing an anti-BCMA chimeric antigen receptor (CAR) having an anti-BCMA single-chain variable fragment (scFv) comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 3 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 5.
Engineered CAR domain architecture with selectable transmembrane and co-stimulatory domains and CD3zeta activating domain
The anti-BCMA CAR further includes a transmembrane domain selected from the group consisting of a T cell receptor α chain, a T cell receptor β chain, a CD3 zeta chain, a CD28, a CD3ε, a CD45, a CD4, a CD5, a CD8, a CD9, a CD16, a CD22, a CD33, a CD37, a CD64, a CD80, a CD86, a CD134, a CD137, an ICOS, a CD154, and a GITR; a co-stimulatory domain selected from the group consisting of a CD28, a 4-1BB, a GITR, an ICOS-1, a CD27, an OX-40, and a DAP10; and a CD3zeta activating domain.
Overall, the claims cover a tumor-decreasing method using engineered immune cells expressing an anti-BCMA CAR that combines a humanized BCMA (PMC306) scFv defined by VH=SEQ ID NO:3 and VL=SEQ ID NO:5 with a CAR domain architecture including a selectable transmembrane domain, a selectable co-stimulatory domain, and a CD3ζ activating domain. Dependent refinements include specifying the engineered immune cell types and constraining particular CAR domain selections.
Stated Advantages
Decreases growth of a BCMA-positive tumor.
Documented Applications
A method of decreasing growth of a BCMA-positive tumor by contacting the tumor with engineered immune cells expressing the specified anti-BCMA CAR.
Interested in licensing this patent?